Journal
JOURNAL OF CHEMICAL INFORMATION AND MODELING
Volume 54, Issue 4, Pages 1070-1082Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ci500077v
Keywords
-
Categories
Funding
- National Library of Medicine [R43 LM011152-01]
- National Institutes of Allergy and Infectious Diseases [2R42AI088893-02]
- NIH/NIAID [2R42A1088893-02]
- Rutgers University-NJMS
Ask authors/readers for more resources
Selecting and translating in vitro leads for a disease into molecules with in vivo activity in an animal model of the disease is a challenge that takes considerable time and money. As an example, recent years have seen whole-cell phenotypic screens of millions of compounds yielding over 1500 inhibitors of Mycobacterium tuberculosis (Mtb). These must be prioritized for testing in the mouse in vivo assay for Mtb infection, a validated model utilized to select compounds for further testing. We demonstrate learning from in vivo active and inactive compounds using machine learning classification models (Bayesian, support vector machines, and recursive partitioning) consisting of 773 compounds. The Bayesian model predicted 8 out of 11 additional in vivo actives not included in the model as an external test set. Curation of 70 years of Mtb data can therefore provide statistically robust computational models to focus resources on in vivo active small molecule antituberculars. This highlights a cost-effective predictor for in vivo testing elsewhere in other diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available